By Stephanie Murg, Managing Director, G2 Intelligence
Genetic diagnostic testing company Claritas Genomics (Cambridge, Mass.) has secured $15 million to fund expansion of its commercial operations and launch novel next generation sequencing-based tests for diagnosis of pediatric genetic disorders. The Series B round, announced Monday, was led by WuXi NextCODE Genomics with return investors Boston Children’s Hospital, Cerner Corporation, and Cincinnati Children’s Hospital Medical Center.
Formed in January 2013 when Boston Children’s Hospital spun out its molecular testing laboratory into a fully commercial CLIA-certified laboratory, Claritas Genomics aims to “enable providers to integrate genomics into the future of routine medical practice.” The company positions itself as applying a “systems approach” to diagnostic medicine, partnering with not only ordering clinicians but also genetic researchers and its investor base of healthcare providers and technology firms.
News of this latest investment round follows a busy 2014 for Claritas. Early last year the company obtained a contract with the Million Veteran Program to sequence 19,000 exomes for research, and last month the company partnered with NextCODE Health to use the NextCODE software platform to expedite test performance and results delivery. Claritas also recently brought on industry veteran Patrick Terry to serve as chief commercial officer.